Brief: Vanda Pharmaceuticals Announces FDA Acceptance Of Biologics License Application Filing For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis
25/02/2026 12:21
Feb 25 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O: VANDA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FILING FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS VANDA PHARMACEUTICALS INC - TARGET ACTION DATE OF DECEMBER 12, 2026 Source text: ID:nPnblqm0Ta Further company coverage: VNDA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vanda Pharmaceuticals
See all newsUS STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
US STOCKS ON THE MOVE-Nvidia, Penske Automotive, ManpowerGroup
US STOCKS ON THE MOVE-Barrick Mining, Venture Global, GE Vernova
Vanda Pharma shares slip as trial failure halts anxiety drug program